New kidney drug goes Head-to-Head with standard treatment
NCT ID NCT07304817
Summary
This study aims to compare how two different drugs, vicadrostat and spironolactone, affect kidney function and proteins in the blood and urine of people who have both chronic kidney disease and heart disease or heart failure. About 100 participants will take one of the drugs along with a common diabetes/heart medication (empagliflozin) for 26 weeks. The goal is to understand which drug might work better to protect the kidneys in these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Delphinium
Groningen, Provincie Groningen, 9713GZ, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Medical Center Groningen
Groningen, Provincie Groningen, 9713GZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.